SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Ghoneim MA, el-Mekresh MM, el-Baz MA, el-Attar IA, Ashamallah A. Radical cystectomy for carcinoma of the bladder: critical evaluation of the results in 1026 cases. J Urol. 1997; 158: 393399.
  • 2
    Bassi P, Ferrante GD, Piazza N, et al. Prognostic factors of outcome after radical cystectomy for bladder cancer: a retrospective study of a homogeneous patient cohort. J Urol. 1999; 161: 14941497.
  • 3
    Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1054 patients. J Clin Oncol. 2001; 19: 666675.
  • 4
    Dalbagni G, Genega E, Hashibe M, et al. Cystectomy for bladder cancer: a contemporary series. J Urol. 2001; 165: 11111116.
  • 5
    Sternberg CN, Calabrò F. Chemotherapy and management of bladder tumors. Br J Urol. 2000; 85: 599610.
  • 6
    Sternberg CN. Current perspectives in muscle invasive bladder cancer. Eur J Cancer. 2002; 38: 460467.
  • 7
    Natale RB, Grossman HB, Blumenstein B, et al. SWOG 8710 (INT-0080): randomized Phase III trial of neoadjuvant M-VAC and cystectomy versus cystectomy alone in patients with locally advanced bladder cancer [abstract]. Proc Am Soc Clin Oncol. 2001; 20: 2a.
  • 8
    Hall RR. Updated results of a randomised controlled trial of neoadjuvant cisplatin (C), methotrexate (M) and vinblastine (V) chemotherapy for muscle-invasive bladder cancer [abstract]. Proc Annu Meet Am Soc Clin Oncol. 2002; 21: 178a.
  • 9
    [No authors listed.] Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. Lancet. 1999; 354: 533540.
  • 10
    Kachnic LA, Kaufman DS, Heney NM. Bladder preservation by combined modality therapy for invasive bladder cancer. J Clin Oncol. 1997; 15: 10221029.
  • 11
    Zietman AL, Grocela J, Zehr E, et al. Selective bladder conservation using transurethral resection, chemotherapy, and radiation: management and consequences of Ta, T1, and Tis recurrence within the retained bladder. Urology. 2001; 58: 380385.
  • 12
    Shipley WU, Winter KA, Kaufman DS, et al. Phase III trial of neoadjuvant chemotherapy in patients with invasive bladder cancer treated with selective bladder preservation by combined radiation therapy and chemotherapy: initial results of Radiation Therapy Oncology Group 89-03. J Clin Oncol. 1998; 16: 35763583.
  • 13
    Sternberg CN, Arena MG, Calabresi F, et al. Neo-adjuvant M-VAC (methotrexate, vinblastine, Adriamycin and cisplatin) for infiltrating transitional cell carcinoma of the urothelium. Cancer. 1993; 72: 19751982.
  • 14
    Sternberg CN, Pansadoro V, Calabrò F, et al. Neo-adjuvant chemotherapy and bladder preservation in locally advanced transitional cell carcinoma of the bladder. Ann Oncol. 1999; 10: 13011305.
  • 15
    Scher HI, Yagoda A, Herr HW, et al. Neoadjuvant M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) effect on the primary bladder lesion. J Urol. 1988; 139: 470474.
  • 16
    Solsona E, Iborra I, Ricos JV, Monros JL, Casanova J, Calabuig C. Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: long-term follow-up of a prospective study. J Urol. 1998; 159: 9599.
  • 17
    Herr HW. Transurethral resection of muscle-invasive bladder cancer: 10-year outcome. J Clin Oncol. 2001; 19: 8993.
  • 18
    Schultz PK, Herr HW, Zhang Z. Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients with M-VAC with 5 years follow-up. J Clin Oncol. 1994; 12: 13941401.
  • 19
    Millikan R, Dinney C, Swanson D, et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus adjuvant M-VAC versus cystectomy with both preoperative and postoperative M-VAC. J Clin Oncol. 2001; 19: 40054013.
  • 20
    Hall RR, Roberts JT, Marsh MM. Radical TUR and chemotherapy aiming at bladder preservation. Progr Clin Biol Res. 1990; 353: 163168.
  • 21
    Splinter TAW, Pavone-Macaluso M, Jacqmin D, et al. European Organization for Research and Treatment of Cancer Genitourinary Group Phase II study of chemotherapy in Stage T3-4N0-xM0 transitional cell cancer of the bladder: evaluation of clinical response. J Urol. 1992; 148: 17931796.
  • 22
    Sternberg CN, Pansadoro V, Calabrò F, et al. Can we select patients for bladder preservation based upon response to chemotherapy [abstract]? J Urol. 2000; 163: 216.
  • 23
    Sternberg CN, Calabrò F. The management of bladder cancer in the elderly. Tumori. 2002; 88(1 Suppl 1 ): S128S129.
  • 24
    Hirsch CH. When your patient needs surgery: weighing risks versus benefits. Geriatrics. 1995; 50: 2631.
  • 25
    Herr HW, Bajorin DF, Scher HI. Neoadjuvant chemotherapy and bladder sparing surgery for invasive bladder cancer: ten-year outcome. J Clin Oncol. 1998; 16: 12981301.
  • 26
    Wijkstrom H, Norming U, Lagerkvist M, Nilsson B, Naslund I, Wilund P. Evaluation of clinical staging before cystectomy in transitional cell bladder carcinoma: a long-term follow-up of 276 consecutive patients. Br J Urol. 1998; 81: 686691.
  • 27
    Sternberg CN, Parmar MKB. Neo-adjuvant chemotherapy is not (yet) standard treatment for muscle invasive bladder cancer. J Clin Oncol. 2001; 19 (Suppl 1): 21S26S.
  • 28
    Machin D, Campbell MJ, Fayers PM, Pinol APY. Sample size tables for clinical studies. London: Blackwell, 1997.
  • 29
    Williams SG, Gandour-Edwards R, Deitch AD, et al. Differences in gene expression in muscle-invasive bladder cancer: a comparison of Italian and American patients. Eur Urol. 2001; 39: 430437.
  • 30
    Cote RJ, Esrig D, Groshen S, Jones PA, Skinner DG. p53 and treatment of bladder cancer. Nature. 1997; 385: 123125.